NVS

3 Great Healthcare Stocks to Buy Right Now

By David Moadel, InvestorPlace Contributor
The sector is a safe bet for long-term growth, but which health-care stocks stand to gain the most? Here are three picks to consider today.

Stock Market Today: Merger Monday; Tesla’s Cybertruck Pre-Orders

By Bret Kenwell, InvestorPlace Contributor
Tesla hit 200,000 pre-orders and there was a bevy of M&A to report. Here's what happened in the stock market today.

The Medicines Company News: MDCO Stock Rockets 22% on Novartis Deal

By William White, InvestorPlace Writer
The Medicines Company (MDCO) news for Monday about a $9.70 billion deal with Novartis (NVS) has MDCO stock heading higher.

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline

By Chris Lau, InvestorPlace Contributor
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

10 Great Biotech Stocks to Buy in Q4

By Sarah Smith, Editor-in-Chief, InvestorPlace.com
With FDA Breakthrough Therapy designations and robust drug pipelines, these biotech companies are all stocks to buy for 2020.

3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector

By Louis Navellier, Editor, Growth Investor
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).

10 Smart Dividend Stocks for the Rest of the Year

By James Brumley, InvestorPlace Feature Writer
Ford, Verizon and AbbVie are just a trio of the top dividend stocks to buy for the remainder of 2019, particularly if the broad market hits turbulence.

New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

By William White, InvestorPlace Writer
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.

Continued Smart M&A Moves Will Help Canopy Stock Break Out

By Luce Emerson, InvestorPlace Contributor
Of course, the medical opportunity is massive, but Tilray competitor, Canopy Growth (NYSE:CGC), has been aggressively pursuing a multi-pronged approach that inherently diversifies the future revenue streams. CGC’s vision for THC as an ingredient in an array of consumer products separates them from an increasingly crowded industry.

4 Top Stock Trades for Tuesday: ROKU, ADSK, SPLK, NVS

By Bret Kenwell, InvestorPlace Contributor
Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.

How and Why Tilray Stock Is a Buy Here

By Chris Tyler, InvestorPlace Contributor
Following a long, steep correction and on the heels of earnings, there’s less to fear in stepping into a contrarian position in Tilray stock.

3 Ways to Buy Into the Marijuana Boom Without the Risk

By Aaron Levitt, InvestorPlace Contributor
Forget the volatile marijuana stocks. Their partners could be a better and safer investment for most investors. Here are 3 that stand to benefit from the rise of legal cannabis use.

Don’t Let the Great Q1 Numbers Fool You into Buying Tilray Stock

By Luce Emerson, InvestorPlace Contributor
After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5 percent for the day. However, that optimism has faded rather quickly, and TLRY stock has not been able to capitalize on that momentum.

5 Biotech Stocks for a Long-Lived Portfolio

By Chris Lau, InvestorPlace Contributor
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.

Here’s the Real Problem with Altria Overpaying for CRON Stock

By Luce Emerson, InvestorPlace Contributor
Altria Group Inc (NYSE:MO) was the latest in a frenzied string of M&A and partnerships in the cannabis sector. Marijuana stocks have been the target of billion-dollar investments, and the $102 billion market cap company and owner of veteran cigarette brands Marlboro, Parliament, and Virginia Slims, last month that it was investing approximately $1.8 billion in Canadian-based Cronos Group Inc (NASDAQ:CRON), which is listed both on the TSX as well as the NASDAQ.

3 Big Stock Charts for Wednesday: Incyte, FMC and LyondellBasell

By James Brumley, InvestorPlace Feature Writer
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.

Novartis News: NVS Stock Sinks Following Alcon Spin-Off

By William White, InvestorPlace Writer
Novartis news about the company's spin-off of Alcon into its own publicly-traded company has NVS stock falling hard on Tuesday.

The Roche Merger Will Do Wonders for Spark Stock

By Chris Lau, InvestorPlace Contributor
As Spark Therapeutics gets acquired, existing shareholders, and Roche investors, will need to eveluate the merits of the deal.

Is Tilray Stock a Must-Buy Following New Partnership?

By Bret Kenwell, InvestorPlace Contributor
Tilray stock is still very expensive, even after its partnership with Novartis' Sandoz. However, TLRY is in a very tradable range.
Load More